uniQure N.V. filings document regulatory, financial, governance, and capital-structure disclosures for a Nasdaq-listed gene therapy company incorporated in the Netherlands. Form 8-K reports cover operating results, corporate updates, Regulation FD disclosures, and clinical or regulatory communications involving programs such as AMT-130 for Huntington’s disease.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also includes formal disclosure categories for material agreements, financing arrangements, risk-related updates, and capital-structure matters connected to uniQure’s development-stage gene therapy portfolio.
uniQure N.V. (QURE) shareholder JPMorgan Chase & Co. reported beneficial ownership of 5,951,794 ordinary shares, equal to 8.5% of the class. The subsidiaries identified as acquiring the reported securities include JPMorgan Asset Management (UK) Limited, JPMorgan Chase Bank, National Association, J.P. Morgan Investment Management Inc., and J.P. Morgan Wealth Management Solutions Inc.
uniQure N.V. reported additional results from ongoing Phase I/II studies of its Huntington’s disease gene therapy candidate, ifezuntirgene inilparvovec (AMT-130). Against propensity score-matched external controls, the 36-month analysis of 15 high-dose patients reported 80% slowing on cUHDRS (nominal p=0.005) and 67% on TFC (nominal p=0.011). At 48 months, 12 high-dose patients showed 44% slowing on cUHDRS (non-significant p=0.144) and 61% on TFC (nominal p=0.008).
At 48 months, updated matched controls had 53% missing data; uniQure said faster-progressing patients were more likely to discontinue and this likely understated the treatment effect. At a June 2026 Type B meeting, the FDA communicated that 36-month data from 12 high-dose patients would be acceptable as the primary basis for a BLA under accelerated approval; the BLA submission preceded and did not include today’s results. Five high-dose participants (17%) had treatment-related serious adverse events of central nervous system inflammation, all resolved.
uniQure N.V. (QURE) reported that it has submitted a Biologics License Application (BLA) to the U.S. FDA seeking accelerated approval of ifezuntirgene inilparvovec (AMT-130), an investigational gene therapy for Huntington’s disease. The company also submitted a Marketing Authorisation Application (MAA) to the U.K. MHRA for the same therapy.
Both applications are supported by a three-year data analysis from a Phase I/II study in which the therapy demonstrated a slowing of disease progression compared with an external Enroll-HD control. uniQure has requested FDA priority review and plans to present a four-year data analysis before the end of the current third quarter. Ifezuntirgene inilparvovec has received FDA Breakthrough Therapy, Regenerative Medicine Advanced Therapy and Fast Track designations.
uniQure N.V. (QURE) received an updated Schedule 13G/A from a group of affiliated Susquehanna entities, reporting aggregate beneficial ownership of 3,339,231 Ordinary Shares of EUR 0.05 par value. This represents 4.8% of the company’s outstanding Ordinary Shares as of June 30, 2026.
The shares are held across G1 Execution Services, LLC, SIG Brokerage, LP, Susquehanna Fundamental Investments, LLC, Susquehanna Portfolio Strategies, LLC and Susquehanna Securities, LLC, which may be deemed a group. The reported holdings include options to buy 2,577,700 shares within Susquehanna Securities, LLC and options held by SIG Brokerage, LP. Each reporting person states it has sole voting and dispositive power over its directly held shares and shared power over all group-held shares, while disclaiming beneficial ownership of shares directly owned by the other reporting persons.
RTW Investments, LP and Roderick Wong, M.D. report beneficial ownership of Ordinary Shares of uniQure N.V. Each reporting person is deemed to beneficially own 3,941,572 Shares, representing 5.7% of the class.
The percentage is based on 63,067,485 Shares outstanding as of May 1, 2026, as reported by the company, plus 5,686,813 Shares issued in a public offering that closed on June 25, 2026. The reporting persons have no sole voting or dispositive power, but share voting and dispositive power over the 3,941,572 Shares, which are directly held by certain RTW funds.
uniQure N.V. reported second quarter 2026 results and updated progress across its gene therapy pipeline. U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease remain on track for the third quarter of 2026, with topline four-year Phase I/II data expected in September 2026. Early data from the first cohort of the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed biological signals of therapeutic activity and a favorable safety profile, and work continues on AMT-191 for Fabry disease.
The company strengthened its balance sheet through a $259 million follow-on offering, contributing to cash, cash equivalents and current investment securities of $810.3 million as of June 30, 2026, up from $622.5 million as of December 31, 2025; management expects these resources to fund projected operating expenses into 2030. Second quarter 2026 revenue was $5.8 million, research and development expenses were $34.0 million and selling, general and administrative expenses were $17.4 million. Higher other expenses and unfavorable non‑operating items led to a net loss of $81.1 million, or $1.22 per share, compared with a net loss of $37.7 million, or $0.69 per share, a year earlier.
Aberdeen Group plc and its subsidiary abrdn Inc. report updated passive ownership in uniQure N.V. under Amendment No. 4 to Schedule 13G. As of June 30, 2026, they beneficially own 2,848,117 ordinary shares, representing 4.52% of the outstanding ordinary-share class.
The group reports no sole voting or dispositive power over these shares. All 2,848,117 shares are held with shared voting and shared dispositive power, principally through abrdn Inc. on behalf of underlying clients, reflecting ownership of less than 5% of the class.
JPMorgan Chase & Co. has reported beneficial ownership of 4,866,211 Ordinary Shares of uniQure N.V., representing 7.0% of this class of securities. The shares are identified by CUSIP N90064101 and relate to Ordinary Shares with a par value of 0.05.
JPMorgan has sole voting power over 4,598,521 shares and shared voting power over 10 shares. It has sole dispositive power over 4,866,201 shares and shared dispositive power over 10 shares. The position is held through subsidiaries including J.P. Morgan Securities LLC, JPMorgan Chase Bank, National Association, JPMorgan Asset Management (UK) Limited, and J.P. Morgan Investment Management Inc.
uniQure N.V.’s CEO Matthew C. Kapusta exercised stock options and sold shares in a pre-planned trade. On July 2, 2026, he exercised options for 21,082 Ordinary Shares at an exercise price of $19.39 per share and converted them into common equity.
That same day, he sold 21,082 Ordinary Shares in three open-market transactions at reported weighted average prices of $44.43, $45.43, and $45.89, with actual sale prices ranging from $44.10 to $46.10. Following these transactions, he directly owned 519,227 Ordinary Shares. The filing states the trades were executed under a Rule 10b5-1 sales plan adopted on October 5, 2025, indicating they were pre-scheduled.